Navigation Links
Cord Blood America CEO Matthew Schissler Discusses Projects in China, South America, 'Afford-A-Cord,' and Profitability

LAS VEGAS, Sept. 16 /PRNewswire/ -- Cord Blood America, Inc. ( (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that Matthew Schissler, its co-founder and CEO, was interviewed by analyst Francis Gaskins on the Company's current accomplishments and future business strategies.

The entire interview is available at:

  • Progress continues in China, with expectations that a temporary laboratory will be in place this year and the processing of samples can begin in 2010,  which will derive revenues for Cord Blood America.  The major, permanent, state-of-the-art laboratory being constructed there will be completed in two – three years.
  • The Company will close its acquisition of controlling interest in BioCells, Inc., Buenos Aires, Argentina, shortly.  "Argentina is a fast growing market and gives us the opportunity to expand throughout South and Central America," Mr. Schissler said.  Also, because the company is profitable, the acquisition will produce positive results for Cord Blood America from the first day.  Mr. Schissler said significant translation issues with a large number of documents slowed the process from an August closing.
  • "Afford-A-Cord," which Cord Blood America announced with fanfare in June, which allows families to store their baby's umbilical cord blood at a significantly reduced rate at the time of birth, has increased in sales each month it has been offered.  Mr. Schissler said there is an educational process involved but the Company is very encouraged by results up to this time.
  • The collection of placentas by CBAI for a major tissue bank in the U.S. now accounts for five percent of the Company's revenues, with significant growth expected.  "We will continue to focus on adding other revenue diversification programs, which reduces risk and makes our revenue model more secure," Mr. Schissler said.
  • Finally, Cord Blood America's CEO said, "Profitability is the Company's number one goal and, once profitable, this will open up larger and better opportunities for CBAI's future."

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at For investor information, visit


Paul Knopick
E & E Communications

SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Launch Warrant Exchange Offer
2. China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results
3. Cord Blood America Says Outreach Program to OB/GYN Nurses, Insurance Case Workers, Paying Significant Dividends
4. New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments
5. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
6. Cord Blood America Reports 12% Increase in 2010 Second Quarter Revenue
7. China Cord Blood Corporation Announces Cancellation of Nine Million Management Incentive Warrants
8. China Cord Blood Corporation Joins Russell Global Index
9. Progenika Biopharma Grants Grifols World-Wide Distribution Rights for the BLOODCHIP® Genotyping Test for Blood Donors
10. Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank
11. Scientists Give the Go-Ahead for Private Storage of Stem Cells From Umbilical Cord Blood
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... 2015 2 nouvelles études permettent d ... les différences entre les souches bactériennes retrouvées dans la plaque ... êtres humains . Ces recherches  ouvrent une nouvelle ... en charge efficace de l,un des problèmes de ... .    --> 2 nouvelles études permettent ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig ... report titled, "DNA Synthesis and Biosecurity: Lessons Learned and ... Department of Health and Human Services guidance for synthetic ... 2010. --> --> ... also has the potential to pose unique biosecurity threats. ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):